Powering Into the Close: Biotech and Blockchain Light Up Late Session

August 20, 2025

DENVER, Colo., Aug 20, 2025 (247marketnews.com)- Tharimmune (NASDAQ:THAR) is extending gains, heading into the close, after releasing positive pharmacokinetic (PK) simulation results for TH104, its buccal film formulation of nalmefene developed to protect military and first responders from high-potency synthetic opioids like weaponized fentanyl.

The potential to offer 24-hour prophylactic coverage versus naloxone’s 30–90 minute rescue window places TH104 in a powerful position as a next-gen defense product. The news kept volume elevated well into the final hour.

NovaBay Pharmaceuticals (NYSE:NBY) hit a 52-week high of $1.25 after announcing a $6 million securities purchase agreement with investor David Lazar. The fresh capital gives the microcap a clear financial runway for continued product development and operational growth.

LIXTE Biotechnology (NASDAQ:LIXT) continued to build on its technical strength heading into the close, with MACD trending higher and the 9EMA crossing the 50-day, a sign that momentum could be just getting started.

The move follows recent data from the Netherlands Cancer Institute, published in Cancer Discovery, highlighting that LB-100 induces “lethal activation” in colon cancer cells by overactivating tumor signaling pathways.

Currently in trials with Roche’s (OTCQX:RHHBY) atezolizumab and GSK’s (NYSE:GSK) dostarlimab, LB-100 is drawing rising investor attention.

A big M&A play fueled activity in the biotech space. XOMA Royalty (NASDAQ:XOMA) announced a definitive agreement to acquire all shares of Mural Oncology (NASDAQ:MURA), forming XRA 5 Corp. to execute the deal.

The move underscores the rising value of early-stage oncology assets and sent both tickers trading with elevated volume.

Rocket Pharmaceuticals (NASDAQ:RCKT) confirmed the FDA lifted the clinical hold on its Phase 2 trial for RP-A501, a gene therapy for Danon disease, a rare, fatal cardiac condition. The revised protocol includes a lower dose and refined immunosuppression modeled after pediatric data.

Trinity Biotech (NASDAQ:TRIB) confirmed it received regulatory clearance to outsource manufacturing of its WHO-prequalified TrinScreen HIV test, a pivotal move in its broader global expansion strategy.

Shineco (NASDAQ:SISI) remained volatile and elevated through the session after unveiling the first on-chain platform for tokenized biological cellular assets, in partnership with Plus Me Limited. The new Cell Infusion Redemption Tokens can be used for stem cell therapies, and are burned upon redemption, adding scarcity to the tokenomics.

Propanc Biopharma (NASDAQ:PPCB) successfully completed its IPO — though financial terms weren’t disclosed — and aims to advance its cancer stem cell-targeting therapy, PRP, into clinical trials.

For additional 247marketnews.com and LIXT disclosure https://247marketnews.com/lixte-biotechnology/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (RCKT, LIXT, TRIB, MURA, NBY, SISI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.